Inovio Pharmaceuticals, Inc. (INO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Inovio Pharmaceuticals, Inc. (INO) is down 30.5% since the beginning of the year. At $1 per share, INO is trading 59.4% below its 52-week high of $3. Investors who bought $1,000 worth of INO shares 5 years ago would now be looking at an investment worth $13.

Inovio Pharmaceuticals, Inc. (INO) has returned -30.46% so far this year and -42.38% over the past 12 months. Over the last ten years, INO has returned -37.50% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Dec 8, 1998, INO's average daily return is +0.12%, while the average monthly return is +1.48%. At this rate, an investment would double in approximately 3.9 years.

Historically, 43% of months were positive and 57% were negative. The best month was Dec 2008 with a return of +181.1%, while the worst month was Jul 2000 at -59.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, INO closed higher 43% of trading days. The best single day was Jul 29, 2009 with a return of +329.7%, while the worst single day was Jul 27, 2000 at -55.3%.

Inovio Pharmaceuticals, Inc. has an annualized alpha of 26.01%, beta of 0.75, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 09, 1998.

• This stock participated in 193.49% of S&P 500 Index downside but only 98.59% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INO ranks 20 for risk / return — below 20% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Inovio Pharmaceuticals, Inc. (INO) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Inovio Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Inovio Pharmaceuticals, Inc. was 99.95%, occurring on Apr 7, 2026. The portfolio has not yet recovered.

The current Inovio Pharmaceuticals, Inc. drawdown is 99.95%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Inovio Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Inovio Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.